TNFRSF8 and Hodgkins lymphoma: Brentuximab vedotin (BV), an anti-CD30 Ab conjugated to the microtubule inhibitor monomethyl auristatin E (MMAE), has demonstrated efficacy in treating relapsed/refractory Hodgkin lymphoma (R/R HL) and systemic anaplastic large-cell lymphoma.